JAZZ — Jazz Pharmaceuticals plc stock price, charts and financials

QT88Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
258.09
+1.53+0.60%
OverviewShort InterestFilings
JAZZQT88Jazz Pharmaceuticals plc·NASDAQ
258.09+0.60%
News
Up 0.6% — Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects (zacks.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ASND-1.58%$251.38NBIX+0.93%$164.93BBIO+0.58%$84.97GMAB-1.52%$30.78EXEL-2.35%$52.80ARWR+0.64%$88.21BMRN+6.89%$68.20HALO-0.08%$103.04
Snapshot
Index-P/E16.88EPS (ttm)15.20Insider Own4.00%Shs Outstand62.82MPerf Week1.46%
Market Cap16.12BForward P/E9.90EPS next Y25.92Insider Trans-4.51%Shs Float61.98MPerf Month3.91%
Enterprise Value18.91BPEG0.00EPS next Q-Inst Own-Short Float6.13%Perf Quarter13.04%
Income934.76MP/S3.50EPS this Y22653.83%Inst Trans-Short Ratio4.12Perf Half Y57.25%
Sales4.60BP/B3.38EPS next Y3.57%ROA8.49%Short Interest3.80MPerf YTD50.92%
Book/sh-P/C9.76EPS next 5Y9.00%ROE21.37%52W High266.62 -3.20%Perf Year142.20%
Cash/sh-P/FCF10.45EPS past 3/5Y-ROIC14.46%52W Low107.29 140.56%Perf 3Y97.07%
Dividend Est.-EV/EBITDA12.81Sales past 3/5Y5.27% 12.54%Gross Margin84.67%Volatility3.11% 2.97%Perf 5Y51.34%
Dividend TTM-EV/Sales4.11EPS Y/Y TTM-98.73%Oper. Margin31.05%ATR (14)7.23Perf 10Y67.88%
Dividend Ex-Date-Quick Ratio1.58Sales Y/Y TTM9.09%Profit Margin20.45%RSI (14)58.06Recom2.10
Dividend Gr. 3/5Y-Current Ratio1.78EPS Q/Q277.38%SMA202.04%Beta0.36Target Price282.08
Payout0.00%Debt/Eq0.92Sales Q/Q19.04%SMA506.30%Rel Volume1.10Prev Close256.56
Employees2,890LT Debt/Eq1.01EarningsNov 04SMA20031.96%Avg Volume863.61KPrice258.09
IPO DateJun 01, 2007Option/ShortYes / YesEPS/Sales Surpr.36.60% 9.22%Net Debt/EBITDA1.89Volume949,560Change0.60%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-04-26ReiteratedDeutsche BankBuy$270 → $287
Aug-04-26ReiteratedTruist FinancialBuy$264 → $300
Aug-04-26ReiteratedUBSBuy$307 → $315
Aug-04-26ReiteratedStifel NicolausBuy$230 → $275
Aug-04-26ReiteratedRobert W. Baird$252 → $280
Aug-04-26ReiteratedMorgan StanleyOverweight$245 → $280
Aug-04-26ReiteratedWells FargoOverweight$285 → $300
Aug-04-26ReiteratedPiper SandlerOverweight$301 → $310
Aug-04-26ReiteratedNeedhamBuy$235 → $292
Aug-04-26ReiteratedBarclaysOverweight$260 → $270
Latest News
Today
Today10:16AM
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospectszacks.com
07:30AM
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolioprnewswire.com
Aug-07-26
Aug-07-2610:51AM
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Termzacks.com
Aug-06-26
Aug-06-2612:41PM
JAZZ vs. TECH: Which Stock Is the Better Value Option?zacks.com
Aug-05-26
Aug-05-2607:30AM
Jazz Pharmaceuticals' Re-Rating Story Has Legsseekingalpha.com
05:26AM
Jazz Pharmaceuticals PLC $JAZZ Stake Boosted by Bank of America Corp DEdefenseworld.net
04:09AM
Amundi Acquires 53,454 Shares of Jazz Pharmaceuticals PLC $JAZZdefenseworld.net
Aug-04-26
Aug-04-2602:46PM
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 Viewzacks.com
07:54AM
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Resultsbenzinga.com
Aug-03-26
Aug-03-2609:09PM
Jazz Pharmaceuticals plc (JAZZ) Q2 2026 Earnings Call Transcriptseekingalpha.com
09:01PM
Compared to Estimates, Jazz (JAZZ) Q2 Earnings: A Look at Key Metricszacks.com
07:46PM
Jazz Pharmaceuticals (JAZZ) Q2 Earnings Lag Estimateszacks.com
06:04PM
Jazz Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
04:05PM
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Resultsprnewswire.com
Jul-30-26
Jul-30-2601:20AM
Aristotle Global Equity Advisory Q2 2026 Portfolio Reviewseekingalpha.com
Company

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,6014,2684,069——————
Cost of Goods Sold Incl. D&A705503446——————
Gross Profit3,8963,7643,623——————
Selling, General and Administrative Excl. Other1,6791,8091,385——————
Research and Development754783884——————
Other Operating Expense35948638——————
Operating Income1,429224717——————
Interest Expense194195238——————
Unusual Expense
—————————
Non-Operating Income (Expense)-507-658-10——————
Net Income Before Taxes727-629469——————
Income Taxes-213-272-91——————
Consolidated Net Income940-356560——————
Net Income From Continuing Operations940-356560——————
Net Income940-356560——————
EPS (Recurring)15.20-5.849.06——————
EPS (Basic, Before Extraordinaries)15.20-5.849.06——————
EPS (Diluted)14.63-5.848.65——————
EBITDA1,4771081,522——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio17.64—14.24——————
Price To Sales Ratio3.532.431.88——————
Gross Margin84.6888.1989.04——————
Operating Margin31.065.2517.62——————
Net Margin20.43-8.3413.76——————
Shares Outstanding636162——————
Market Capitalization16,26010,3707,635——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$284.97$234.37$183.78$133.18$82.58● Close Price0.00M5.20M10.41M15.61M20.81MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
COZADD BRUCE CDirectorAug 03 '26Sale252.986,0001,517,880360,682Aug 05
COZADD BRUCE CDirectorJul 01 '26Sale240.476,0001,442,820366,682Jul 06
Smith Mark DouglasDirectorJun 15 '26Sale230.551,157266,7469,680Jun 17
Patil Neena MEVP & Chief Legal OfficerJun 10 '26Sale231.831,200278,19651,549Jun 12
Pearce SamanthaEVP, Chief Commercial OfficerMay 28 '26Sale235.416,9071,625,97750,272Jun 01
Patil Neena MEVP & Chief Legal OfficerMay 28 '26Sale236.971,192282,46852,626Jun 01
Pearce SamanthaEVP, Chief Commercial OfficerMay 28 '26Option Exercise109.456,907755,97157,179Jun 01
Mulligan SeamusDirectorMay 28 '26Option Exercise138.083,415471,5431,183,028Jun 01
McSharry Heather AnnDirectorMay 22 '26Sale241.002,000482,00018,449May 27
Winningham Rick EDirectorMay 22 '26Option Exercise138.083,415471,54312,308May 27
Winningham Rick EDirectorMay 22 '26Sale241.572,741662,1439,567May 27
COZADD BRUCE CDirectorMay 01 '26Sale203.336,0001,219,980378,682May 05
COZADD BRUCE CDirectorApr 01 '26Sale190.506,0001,143,011384,682Apr 03
Carr PatriciaSVP, Chief Accounting OfficerMar 09 '26Sale182.941,287235,4446,512Mar 09
COZADD BRUCE CDirectorMar 03 '26Sale186.446,0001,118,613405,796Mar 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.